The presence of the PNPLA3 148M variant is associated with hepatic steatosis in GWAS population studies [3] and the lowering of PNPLA3 expression with antisense oligonucleotides has been shown to reduce hepatic fat in rodents [13,22]. This evidence concerns the gene PNPLA3 and fatty liver disease.